Proteins comprising an IgG2 domain
View Patent ↗Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.
1. An antibody or Ig fusion protein comprising an IgG2 antibody moiety comprising an IgG2 hinge, wherein the IgG2 hinge has been mutated to contain two cysteines.
2. A protein comprising an immunoglobulin moiety comprising: an antibody heavy chain comprising an IgG1 hinge and an IgG2 CH2 domain, and an antibody light chain, which together with the antibody heavy chain forms an antigen binding site directed against a tumor-associated antigen, wherein the most N-terminal cysteine of the hinge is mutated.
3. The protein of claim 2 , comprising an inactive Fc receptor I binding site.
4. A protein comprising an immunoglobulin moiety comprising: an antibody heavy chain comprising an IgG1 hinge and an IgG2 CH2 domain, and an antibody light chain, which together with the antibody heavy chain forms an antigen binding site directed against a protein or glycolipid antigen, wherein the most N-terminal cysteine of the hinge is mutated.
5. A protein comprising an immunoglobulin moiety comprising an antigen binding site and a heavy chain comprising an IgG1 hinge and an IgG2 CH2 domain, wherein the IgG1 hinge comprises fewer than three cysteines, wherein the most N-terminal cysteine of the hinge is mutated.
6. A protein comprising an immunoglobulin moiety comprising an antigen binding site and a heavy chain comprising an IgG1 hinge and an IgG2 CH2 domain, wherein the immunoglobulin moiety is fused to a non-immunoglobulin moiety, wherein the most N-terminal cysteine of the hinge is mutated.
7. The fusion protein of claim 6 , wherein the non-immunoglobulin moiety is a cytokine.
8. The fusion protein of claim 7 , wherein the cytokine is interleukin-2.
9. The fusion protein of claim 6 , wherein the non-immunoglobulin moiety is fused to the C-terminus of the immunoglobulin moiety.
10. A protein comprising an immunoglobulin moiety comprising: an antibody heavy chain comprising an IgG1 hinge and an IgG2 CH2 domain, and an antibody light chain, which together with the antibody heavy chain forms an antigen binding site, wherein the antigen is a human antigen, wherein the most N-terminal cysteine of the hinge is mutated.
11. A protein comprising an immunoglobulin moiety comprising: an antibody heavy chain comprising an IgG1 hinge and an IgG2 CH2 domain, and an antibody light chain, which together with the antibody heavy chain forms an antigen binding site, wherein the antigen is present in a body tissue, wherein the most N-terminal cysteine of the hinge is mutated.
12. A protein comprising an immunoglobulin moiety comprising: an antibody heavy chain comprising an IgG1 hinge and an IgG2 CH2 domain, and an antibody light chain, which together with the antibody heavy chain forms an antigen binding site directed against a diseased cell, wherein the most N-terminal cysteine of the hinge is mutated.
13. The protein of claim 12 , wherein the diseased cell is a virus-infected cell.